Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06948409 · ClinicalTrials.gov registry record
NMBA Reversal and Postoperative Urinary Retention
A clinical trial of Neuromuscular Blockade and Urinary Retention Postoperative, sponsored by Beth Israel Deaconess Medical Center.
- Active
- Registry status
- 70,000
- Enrollment target
- 1
- Study location
NCT06948409 is a study of Neuromuscular Blockade and Urinary Retention Postoperative that is active but no longer recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 70,000 participants, above the 174-participant average among 6 other Neuromuscular Blockade trials with a reported enrollment target (40130% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06948409, a study of Neuromuscular Blockade and Urinary Retention Postoperative, is active but no longer recruiting, sponsored by Beth Israel Deaconess Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 70,000 participants
- Enrollment target
- 1
- Study location
Study Summary
In this single-center retrospective cohort study of adult patients who underwent surgery under general anesthesia at Beth Israel Deaconess Medical Center between September 2016 and January 2024, the association between the choice of neuromuscular blocking agent (NMBA) reversal strategy, comparing sugammadex with neostigmine (combined with a muscarinic antagonist), and postoperative urinary retention (POUR) will be evaluated. In secondary analyses, the effects of NMBA reversal strategy and POUR on costs of care and unplanned hospital visits will be analyzed.
Conditions Studied
Interventions
- DRUG Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70,000 participants |
| Start Date | 2025-06-08 |
| Est. Completion | 2026-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06948409
The ClinicalTrials.gov registry entry for NCT06948409 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 70,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 174-participant average among 6 other Neuromuscular Blockade trials with a reported enrollment target (40130% higher). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Neuromuscular Blockade appearing as the primary indexed condition, and to 1 intervention - of which Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist]) is the first listed.
NCT06948409 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06948409 about?
NCT06948409 is a clinical study titled "NMBA Reversal and Postoperative Urinary Retention". In this single-center retrospective cohort study of adult patients who underwent surgery under general anesthesia at Beth Israel Deaconess Medical Center between September 2016 and January 2024, the association between the choice of neuromuscular blocking agent (NMBA) reversal strategy, comparing su...
What is the current status of trial NCT06948409?
This trial is currently active not recruiting. The enrollment target is 70,000 participants. The study started on 2025-06-08. Estimated completion is 2026-06-01.
What conditions does trial NCT06948409 study?
This clinical trial studies the following conditions: Neuromuscular Blockade, Urinary Retention Postoperative, Sugammadex, Neuromuscular Blocking Agents, Urinary Retention After Procedure.
What interventions are being tested in trial NCT06948409?
The interventions under investigation include: Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist]) (DRUG).
Who is sponsoring clinical trial NCT06948409?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06948409 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuromuscular Blockade
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
RECRUITING · Phase 4
-
Median Versus Ulnar Nerve Quantitative Electromyography Neuromuscular Blockade Monitoring Comparison
RECRUITING
-
Understanding the Cognition and Decision Making of Community Anesthesiologists
COMPLETED
-
Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular
COMPLETED · Phase 4
-
Comparison of Onset of Neuromuscular Blockade With Electromyographic and Acceleromyographic Monitoring
COMPLETED
-
The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications
COMPLETED · Phase 4
Explore more on PlainTrial
Neuromuscular Blockade
All registered trials for this condition
Urinary Retention Postoperative
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.